Kenya's pharma market can expect good growth, despite global conditions; F&S

Expanding therapeutic areas are creating significant opportunities for growth within the Kenyan pharmaceutical industry. Although infectious  diseases are still responsible for the largest burden of disease in  Kenya, non-communicable diseases are becoming a major problem, with the  incidence of type 2 diabetes, cardiovascular disease and cancer  increasing rapidly.

A new report from Frost & Sullivan, Strategic Analysis of the  Pharmaceutical Industry in Kenya, finds that the sector earned $208.6  million in 2007 and estimates this to reach $557.8 million in 2014. The  analysis covered generic pharmaceuticals, branded pharmaceuticals,  anti-diabetic pharmaceuticals, oncology pharmaceuticals, cardiovascular  pharmaceuticals and anti-infective pharmaceuticals, the market research  consultant said.

Diabetes drug market to reach $29M in 2014